+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Australia Antacids Market to Reach US$ 180.51 Million by 2033 - 3.33% CAGR Growth Forecast

  • PDF Icon

    Report

  • 200 Pages
  • July 2025
  • Region: Australia
  • Renub Research
  • ID: 6116602
The Australia Antacids Market is expected to reach US$ 180.51 million by 2033 from US$ 134.42 million in 2024, with a CAGR of 3.33% from 2025 to 2033. Australia's antacid market share is being positively impacted by the growing number of people suffering from gastroesophageal reflux disease (GERD) as well as the growing availability of over-the-counter medications in pharmacies, supermarkets, and online marketplaces.

Australia Antacids Market Overview

Antacids are drugs used to counteract too much stomach acid. They provide alleviation for symptoms such as acid reflux, indigestion, and heartburn. By raising the pH of the stomach's contents, antacids reduce acidity and ease the discomfort that comes with high stomach acid levels, which are acidic.

Antacids are a practical way for people to self-treat minor symptoms because they are available without a prescription. They are widely accessible over-the-counter in a variety of forms, such as chewable tablets, liquids, and tablets. They provide immediate symptom relief.

Antacids have several advantages, such as their quick effectiveness, availability over-the-counter, and variety of formulations to suit personal tastes. For treating the temporary symptoms of excessive stomach acid, antacids are easily obtained and efficient solutions. They currently come in a variety of forms and are effective in terms of flavor and taste.

The market for antacids in Australia is steadily expanding due to the rising incidence of gastrointestinal disorders like indigestion, acid reflux, and heartburn. More people are looking for treatment from acid-related discomfort as a result of shifting lifestyles, including eating habits and increased stress levels.

Antacids are still a common option because of their rapid effect and over-the-counter availability, which allows for prompt symptom relief. From chewable tablets to liquid suspensions, the market offers a broad variety of antacid formulations to accommodate a range of consumer preferences, offering choices appropriate for various age groups and requirements.

Traditional retail pharmacies, hospital pharmacies, and increasingly internet platforms are the distribution channels in the Australian antacid market. The expansion of the online category has been supported by the ease of online buying and consumers' increasing comfort level with digital health transactions.

The market's major players concentrate on developing new products and improving formulations to increase effectiveness and decrease negative effects. Marketing initiatives can promote market expansion by raising awareness of digestive health issues and the significance of prompt treatment. All things considered, the market is influenced by changing consumer tastes, improvements in product offers, and growing accessibility through a variety of distribution channels.

Key Factors Driving the Australia Antacids Market Growth

Growing Incidence of Gastrointestinal Diseases

One of the main factors propelling the expansion of the antacids market in Australia is the rising incidence of gastrointestinal diseases like heartburn, acid reflux, and indigestion. People want immediate and efficient alleviation from these conditions since they are uncomfortable and interfere with day-to-day living.

As a first-line treatment, antacids neutralize stomach acid and quickly reduce symptoms. Environmental causes and aging populations are responsible for the increase in these ailments, which has resulted in a greater number of patients in need of symptomatic care.

More people are expected to identify symptoms early and choose antacid treatments as awareness of these conditions increases, which will increase market demand. This trend emphasizes how crucial it is to have antacid products that are both dependable and easily accessible in order to satisfy consumer demands.

Changing Dietary Habits and Lifestyles

The rising prevalence of digestive issues is mostly caused by modern lifestyles marked by hectic schedules, erratic eating habits, and a greater intake of spicy, processed, and quick foods. Furthermore, drinking alcohol and experiencing high amounts of stress make gastrointestinal issues like heartburn and acid reflux worse.

Antacid use is fueled by these lifestyle circumstances, which raise the urge for quick fixes that work. Antacids are a popular choice because consumers want immediate relief that fits into their busy schedules.

This change in eating patterns and lifestyle choices reveals a developing market niche devoted to treating sporadic digestive issues, which encourages producers to develop and provide a range of antacid formulations that are easy to use.

Growing Awareness and Self-Medication

The Australian population's growing health consciousness has resulted in a better comprehension of gut health and the significance of prompt symptom management. For mild stomach discomfort, many customers now choose over-the-counter (OTC) remedies like antacids, avoiding more involved or prescription-based therapies when they are not required.

Antacid medications are easily accessible through pharmacies, supermarkets, and internet platforms, which supports the growing tendency of self-medication. Additionally, programs for health education and advertising have raised awareness of the causes and solutions of acid-related problems, promoting preventative health care.

Customers are thus empowered to choose antacids as a potent, quick-acting remedy, which supports the market's consistent expansion.

Challenges in the Australia Antacids Market

Increasing Preference for Prolonged Therapy

The growing preference for long-term therapeutic options like proton pump inhibitors (PPIs) and H2 receptor blockers presents a significant challenge for the Australian antacid market.

Healthcare providers frequently prescribe these drugs for severe or chronic episodes of acid reflux and associated disorders because they provide long-lasting acid control. Because traditional antacids only offer temporary symptom alleviation, individuals with chronic complaints may choose to avoid them.

This change in treatment preference has an impact on market growth and lowers the frequency of antacid sales. Furthermore, self-medication using over-the-counter medications may not be preferred by patients managing chronic diseases over prescription-based, medically supervised treatments.

In favor of more all-encompassing treatment options, this trend is gradually reducing the market share of traditional antacids.

Regulatory Limitations on Promotion and Claims

Tight regulatory frameworks controlling the promotion of health-related products in Australia pose serious obstacles to the antacids business. Regulatory agencies closely monitor the statements that over-the-counter drugs, such as antacids, can make about their intended usage, safety, and efficacy.

Particularly when it comes to positioning versus alternative digestive health therapies, these limitations may restrict how marketers convey their value propositions to customers. The incapacity of businesses in this sector to effectively promote advantages through packaging and media impedes marketing initiatives and could lower brand awareness.

Operational complexity is further increased by the need for constant monitoring and adaptation in order to comply with changing advertising guidelines. These limitations pose a significant challenge in an industry that is already highly competitive.

Australia Antacids Market Overview by States

Due to increased access to urban healthcare, antacids are becoming more and more popular in Queensland and Western Australia, while demand is still high in New South Wales and Victoria. The following provides a market overview by states:

New South Wales Antacids Market

New South Wales dominates Australia's antacid market thanks to its sophisticated healthcare system and big urban population. Due to the high frequency of gastrointestinal disorders in the state, including heartburn, acid reflux, and indigestion, many people turn to over-the-counter antacid medicines in an attempt to quickly alleviate their symptoms.

The region's pharmacies, supermarkets, and internet merchants provide a wide range of antacid formulas, including tablets and liquids. Increased self-medication with antacids for moderate and sporadic symptoms is a result of growing awareness of digestive health.

Customers place a high importance on price and accessibility, particularly when managing stomach issues brought on by lifestyle choices. Consequently, New South Wales continues to be a major contributor to the growth of the Australian antacid market as a whole.

Victoria Antacids Market

One of Australia's most important antacid markets is Victoria, which is home to big cities like Melbourne. People who live in cities have easy access to pharmacies, shops, hospitals, and expanding internet marketplaces that sell antacids.

Over-the-counter antacids are being used more and more to treat common digestive issues like heartburn and indigestion, which are frequently brought on by stress and contemporary eating habits. For quick symptom relief, Victoria consumers frequently turn to chewable tablets or liquid formulations because they value ease and familiarity in treatment.

Although e-commerce is becoming more popular among tech-savvy consumers, retail pharmacies continue to be the primary purchasing route. Victoria is positioned as a major contributor to the growth of the national antacids market due to increased knowledge of digestive health issues and the accessibility of antacid solutions.

Queensland Antacids Market

The market for antacids in Queensland is expanding due to rising awareness of digestive health issues and easy availability to over-the-counter medications in both urban and rural areas. Antacid tablets and liquids are frequently used by residents to treat sporadic symptoms like indigestion and heartburn, especially those brought on by stress and a modern diet.

Supermarkets and retail pharmacies offer wide availability, but internet pharmacies are becoming more popular among tech-savvy customers. OTC treatments' familiarity and ease contribute to their steady growth in regional areas.

Lifestyle elements that promote market expansion include eating habits and self-medication practices. Overall, Queensland continues to play a significant role in the national antacid market, with consumers favoring easily accessible, quick-acting relief products from a variety of distribution channels.

Market Segmentation

Drug Class

  • Proton Pump Inhibitors
  • H2 Antagonist
  • Acid Neutralizers
  • Pro-Motility Agents

Formulation Type

  • Tablets
  • Liquid
  • Powder
  • Others

Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

States

  • New South Wales
  • Victoria
  • Queensland
  • Western Australia
  • South Australia
  • Australian Capital Territory
  • Tasmania
  • Northern Territory

All the Key Players Have Been Covered

  • Overview
  • Key Persons
  • Recent Development
  • SWOT Analysis
  • Revenue Analysis

Company Analysis

  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Pfizer Inc.
  • Procter & Gamble Company
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

Table of Contents

1. Introduction
2. Research & Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.3 Forecast Projection Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Australia Antacids Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 By Drug Class
6.2 By Formulation Type
6.3 By Distribution Channel
6.4 By States
7. Drug Class
7.1 Proton Pump Inhibitors
7.1.1 Market Analysis
7.1.2 Market Size & Forecast
7.2 H2 Antagonist
7.2.1 Market Analysis
7.2.2 Market Size & Forecast
7.3 Acid Neutralizers
7.3.1 Market Analysis
7.3.2 Market Size & Forecast
7.4 Pro-Motility Agents
7.4.1 Market Analysis
7.4.2 Market Size & Forecast
8. Formulation Type
8.1 Tablets
8.1.1 Market Analysis
8.1.2 Market Size & Forecast
8.2 Liquid
8.2.1 Market Analysis
8.2.2 Market Size & Forecast
8.3 Powder
8.3.1 Market Analysis
8.3.2 Market Size & Forecast
8.4 Others
8.4.1 Market Analysis
8.4.2 Market Size & Forecast
9. Distribution Channel
9.1 Retail Pharmacy
9.1.1 Market Analysis
9.1.2 Market Size & Forecast
9.2 Hospital Pharmacy
9.2.1 Market Analysis
9.2.2 Market Size & Forecast
9.3 Online Pharmacy
9.3.1 Market Analysis
9.3.2 Market Size & Forecast
10. Top States
10.1 New South Wales
10.1.1 Market Analysis
10.1.2 Market Size & Forecast
10.2 Victoria
10.2.1 Market Analysis
10.2.2 Market Size & Forecast
10.3 Queensland
10.3.1 Market Analysis
10.3.2 Market Size & Forecast
10.4 Western Australia
10.4.1 Market Analysis
10.4.2 Market Size & Forecast
10.5 South Australia
10.5.1 Market Analysis
10.5.2 Market Size & Forecast
10.6 Australian Capital Territory
10.6.1 Market Analysis
10.6.2 Market Size & Forecast
10.7 Tasmania
10.7.1 Market Analysis
10.7.2 Market Size & Forecast
10.8 Northern Territory
10.8.1 Market Analysis
10.8.2 Market Size & Forecast
11. Value Chain Analysis
12. Porter’s Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Competition
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threats
14. Pricing Benchmark Analysis
14.1 Abbott Laboratories
14.2 AstraZeneca plc
14.3 Bayer AG
14.4 Boehringer Ingelheim International GmbH
14.5 Dr. Reddy’s Laboratories Ltd.
14.6 GlaxoSmithKline plc
14.7 Johnson & Johnson
14.8 Pfizer Inc.
14.9 Procter & Gamble Company
14.10 Sanofi S.A.
14.11 Sun Pharmaceutical Industries Ltd.
14.12 Takeda Pharmaceutical Company Limited
15. Key Players Analysis
15.1 Abbott Laboratories
15.1.1 Overviews
15.1.2 Key Person
15.1.3 Recent Developments
15.1.4 SWOT Analysis
15.1.5 Revenue Analysis
15.2 AstraZeneca plc.
15.2.1 Overviews
15.2.2 Key Person
15.2.3 Recent Developments
15.2.4 SWOT Analysis
15.2.5 Revenue Analysis
15.3 Bayer AG
15.3.1 Overviews
15.3.2 Key Person
15.3.3 Recent Developments
15.3.4 SWOT Analysis
15.3.5 Revenue Analysis
15.4 Boehringer Ingelheim International GmbH
15.4.1 Overviews
15.4.2 Key Person
15.4.3 Recent Developments
15.4.4 SWOT Analysis
15.4.5 Revenue Analysis
15.5 Dr. Reddy’s Laboratories Ltd.
15.5.1 Overviews
15.5.2 Key Person
15.5.3 Recent Developments
15.5.4 SWOT Analysis
15.5.5 Revenue Analysis
15.6 GlaxoSmithKline plc.
15.6.1 Overviews
15.6.2 Key Person
15.6.3 Recent Developments
15.6.4 SWOT Analysis
15.6.5 Revenue Analysis
15.7 Johnson & Johnson
15.7.1 Overviews
15.7.2 Key Person
15.7.3 Recent Developments
15.7.4 SWOT Analysis
15.7.5 Revenue Analysis
15.8 Pfizer Inc.
15.8.1 Overviews
15.8.2 Key Person
15.8.3 Recent Developments
15.8.4 SWOT Analysis
15.8.5 Revenue Analysis
15.9 Procter & Gamble Company
15.9.1 Overviews
15.9.2 Key Person
15.9.3 Recent Developments
15.9.4 SWOT Analysis
15.9.5 Revenue Analysis
15.10 Sanofi S.A.
15.10.1 Overviews
15.10.2 Key Person
15.10.3 Recent Developments
15.10.4 SWOT Analysis
15.10.5 Revenue Analysis
15.11 Sun Pharmaceutical Industries Ltd.
15.11.1 Overviews
15.11.2 Key Person
15.11.3 Recent Developments
15.11.4 SWOT Analysis
15.11.5 Revenue Analysis
15.12 Takeda Pharmaceutical Company Limited
15.12.1 Overviews
15.12.2 Key Person
15.12.3 Recent Developments
15.12.4 SWOT Analysis
15.12.5 Revenue Analysis

Companies Mentioned

The major companies profiled in this Australia Antacids market report include:
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Pfizer Inc.
  • Procter & Gamble Company
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information